Pulmatrix (NASDAQ:PULM) Shares Cross Below 50 Day Moving Average – Here’s Why

Posted by Mitch Edgeman on Apr 2nd, 2026

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report)’s stock price crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $2.39 and traded as low as $1.20. Pulmatrix shares last traded at $1.23, with a volume of 52,945 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulmatrix in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Pulmatrix currently has a consensus rating of “Sell”.

Check Out Our Latest Analysis on PULM

Pulmatrix Price Performance

The company has a market capitalization of $4.82 million, a P/E ratio of -0.94 and a beta of 1.97. The company’s 50-day moving average price is $2.34 and its two-hundred day moving average price is $3.47.

Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its earnings results on Thursday, February 26th. The biotechnology company reported ($0.25) EPS for the quarter.

Hedge Funds Weigh In On Pulmatrix

A hedge fund recently bought a new stake in Pulmatrix stock. Dimensional Fund Advisors LP purchased a new stake in Pulmatrix, Inc. (NASDAQ:PULM – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned approximately 0.30% of Pulmatrix as of its most recent filing with the Securities & Exchange Commission. 11.84% of the stock is currently owned by institutional investors.

About Pulmatrix

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).